Proteros to Provide Discovery Services for Huntington's Foundation | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Proteros Biostructures today said that it has entered into a drug discovery services agreement with the CHDI Foundation, a non-profit scientific organization focused on discovering and developing Huntington's disease therapies.

Under the alliance, Martinsried, Germany-based Proteros will provide structure-based drug discovery services to CHDI using its integrated discovery platform including proprietary X-ray crystallography tools.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.